Author

J. B. A. G. Haanen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:flow cytometry· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

A. A. F. A. Veenhof· 1 shared A. D. Bins· 1 shared A. Gangaev· 1 shared A. Guislain· 1 shared A. Redeker· 1 shared A. Ribas· 1 shared B. Schilling· 1 shared C. Blank· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. F. A. Veenhof

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivJan 28, 2022

Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments.

S. M. Castenmiller, R. de Groot, A. Guislain…·M. C. Wolkers

This study shows that tumor-infiltrating lymphocytes (TILs) can be effectively generated from metastatic NSCLC lesions regardless of location or prior treatments, with 76% showing anti-tumoral activity.

DOI 10.1016/j.iotech.2022.100090

humanexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintDec 24, 2021

OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum

G. Beyrend, T. C. van der Sluis, E. T. I. van der Gracht…·R. Arens

This study shows that OX40 agonism improves PD-L1 checkpoint blockade by altering T cell differentiation, leading to enhanced anti-tumor immunity through dynamic expression of NK and chemokine receptors.

DOI 10.1101/2021.12.24.474145

mousescRNA-seq

𝕏 PostBluesky

ImmunologybioRxivDec 15, 2020

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

A. Gangaev, E. A. Rozeman, M. W. Rohaan…·P. Kvistborg

The paper shows PD-1 blockade in melanoma patients does not increase the breadth or magnitude of melanoma-reactive CD8 T cells in peripheral blood, suggesting PD-1 acts mainly at the tumor site.

DOI 10.1073/pnas.2102849118

humanflow cytometry

𝕏 PostBluesky